Literature DB >> 8791057

Evaluation of c-ras oncogene product (p21) in superficial bladder cancer.

D Fontana1, M Bellina, C Scoffone, E Cagnazzi, S Cappia, F Cavallo, R Russo, E Leonardo.   

Abstract

OBJECTIVES: The aim of our study is the evaluation of the prognostic importance of p21 protein in superficial bladder cancer.
METHODS: One hundred and fourteen patients with an initial diagnosis of monofocal bladder cancer (stage Ta-T1) following TUR were investigated. On the tissue removed by TUR, besides the usual pathological evaluation, an immuno-histochemical investigation was carried out in order to ascertain the presence of c-ras oncogene product (protein p21). The actuarial curves concerning the time free from the first recurrence were computed, comparing different subgroups in regard to protein p21 presence, grade and stage of the tumour.
RESULTS: The analysis of the results shows the importance of tumour stage as a predictor of recurrence, as well as that of the presence of c-ras products. This last factor increases the risk of recurrence almost 2-fold, in the same time lag, for c-ras-positive patients (p < 0.001). The prognostic significance of c-ras is independent of stage.
CONCLUSION: Our data underline the possibility of acquiring important information on the prognosis of superficial bladder cancer patients, pointing out the significance of c-ras oncogene product.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791057     DOI: 10.1159/000473799

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.

Authors:  A Rose; M Grandoch; F vom Dorp; H Rübben; A Rosenkranz; J W Fischer; A-A Weber
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

3.  Inhibitory effect of flavonoids on mutant H-Rasp protein.

Authors:  Tariq A Masoodi; Adel H Alhamdanz
Journal:  Bioinformation       Date:  2010-06-15

4.  H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells.

Authors:  C Li; R-H Teng; Y-C Tsai; H-S Ke; J-Y Huang; C-C Chen; Y-L Kao; C-C Kuo; W R Bell; B Shieh
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

5.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

6.  Ras Isoprenylation and pAkt Inhibition by Zoledronic Acid and Fluvastatin Enhances Paclitaxel Activity in T24 Bladder Cancer Cells.

Authors:  Shaojuan Li; Paul De Souza
Journal:  Cancers (Basel)       Date:  2011-02-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.